Antibody Fragments Market Size Worth $11.36 Billion By 2030

Antibody Fragments Market Growth & Trends

The global antibody fragments market size is expected to reach USD 11.36 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.9% from 2022 to 2030. There has been a steady increase in chronic conditions across the globe owing to the increasing geriatric population and societal behavior changes. The expediting urbanization is leading to the growth of the middle class resulting in people adopting a more sedentary and unhealthier lifestyle, in turn, causing an increase in diseases such as diabetes. The emerging markets are predicted to hold the largest patient burden owing to the significant population growth.

Furthermore, growing investments by the key market players have contributed to the industry growth. For instance, in June 2020, Vanderbilt University Medical Center collaborated with AstraZeneca to advance the company’s coronavirus-neutralizing antibodies into clinical development as a possible combination therapy for the treatment and prevention of COVID-19. These factors would drive the market in the coming years.

Antibodies are an important tool for molecular and protein detection. Even though whole antibodies are preferable for most immunoassay applications, the performance for some experiments is only enhanced by antibody fragments, such as F(ab')2 and Fab. Monoclonal antibodies are a significant class of therapeutic drugs that have received approval to treat various cancers. With more than 80 antibodies already approved for use in various disease indications, these antibodies represent the largest class of biopharmaceuticals. The introduction of smaller, antigen-binding antibody fragments has been growing at a fast pace, which is impacting the industry positively.

Antibody fragments are also anticipated to be preferred over full-chain antibodies due to their lower manufacturing and purification costs. The use of antibody fragments for the treatment of a specific disease may be constrained by strict ICD-10 rules. However, the new advancements in the clinical development of antibody fragments for serious diseases may offer significant market growth opportunities.

 Request a free sample copy or view the report summary: Antibody Fragments Market Report

Antibody Fragments Market Report Highlights

• By specificity, monoclonal antibodies held the largest share in 2021 as they are considered a significant class of therapeutic agents recommended in the therapy of several forms of malignancies

• Based on type, the scFv segment is anticipated to witness the fastest growth in the coming years. They provide several advantages such as multivalency, heterologous production, low molecular weight, and multimeric form over the parent mAb

• By therapy, the monoclonal antibodies segment led the market in 2021. Ranibizumab (Lucentis) captured the largest revenue share in 2021 as these are used for the treatment of visual impairment due to diabetic macular edema, neovascular (wet) age-related macular degeneration (AMD), and others

• By application, the cancer segment is expected to witness the fastest growth over the forecast period owing to the increasing prevalence of cancer globally, which is resulting in the increasing adoption of antibody fragments for therapeutic purposes

• North America dominated the market in 2021 owing to the increasing prevalence of immunodeficiency diseases, which has led to the increasing demand for antibody fragments for research purposes

• Asia Pacific is expected to grow considerably in the future owing to increasing private and public partnership investments in biotech and pharmaceutical research. This has fueled the adoption of antibody fragments

Antibody Fragments Market Segmentation

Grand View Research has segmented the global antibody fragments market based on specificity, type, therapy, application, and region:

Antibody Fragments Specificity Outlook (Revenue, USD Million, 2018 - 2030)

• Monoclonal Antibodies

• Polyclonal Antibodies

Antibody Fragments Type Outlook (Revenue, USD Million, 2018 - 2030)

• FAB

• scFv

• sdAb

• Others

Antibody Fragments Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Monoclonal Antibodies

  • Praxbind (idarucizumab)

  • Ranibizumab (Lucentis)

  • Certolizumab pegol (Cimzia)

  • Iodine (1311) Metuximab/ Licartin

  • Beovu (brolucizumab-dbll)

  • Cablivi (caplacizumab-yhdp)

  • Blinatumomab/

• PAB

  • CroFab

  • Anavip

  • Anascorp

  • Botulism Antitoxin Heptavalent (HBAT)

  • Digibind

  • DigiFab

• Pipeline

  • AFM13

  • HPN-424

  • MGD007

  • Tebotelimab (MGD013)

  • Bentracimab (PB2452)

  • Flotetuzumab (MGD006)

  • AK104

  • Ozoralizumab

  • Sonelokimab (ALX0761)

Antibody Fragments Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer

• Immunodeficiency

• Others

Antibody Fragments Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Russia

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Singapore

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

List of Key Players in Antibody Fragments Market

• Pfizer Inc.

• Albynx

• Novartis AG

• Genentech, Inc.

• AbbVie Inc.

• Bristol-Myers Squibb Company

• Johnson & Johnson Private Limited

• Lilly